Cover Image

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review

Abstract The coronavirus disease pandemic has presented healthcare systems with unprecedented challenges globally and substantially impacted the management of chronic diseases such as schizophrenia. This narrative review highlights the usefulness of long‐acting injectable antipsychotics (LAIs) as ma...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yoshiyo Oguchi (Author), Nobumi Miyake (Author), Kumiko Ando (Author)
Format:	Book
Published:	Wiley, 2024-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Barriers to long‐acting injectable atypical antipsychotic use in Japan: Insights from a comparative psychiatrist survey
by: Yoshiyo Oguchi, et al.
Published: (2024)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023)

Time to rehospitalization in involuntarily hospitalized individuals suffering from schizophrenia discharged on long-acting injectable antipsychotics or oral antipsychotics
by: Ching-Hua Lin, et al.
Published: (2022)

Long-acting antipsychotic treatments: focus on women with schizophrenia
by: Sofia Brissos, et al.
Published: (2024)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021)

Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study
by: Cristiana Montemagni, et al.
Published: (2022)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021)

A case of postpsychotic depression improved by switching antipsychotic monotherapy
by: Yoshiyo Oguchi, et al.
Published: (2023)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021)

Comparison of long-acting injectable antipsychotics with oral antipsychotics and hospital readmission rates in pediatric patients
by: Danial Chowdhury, PharmD, et al.
Published: (2024)

Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution
by: Magdalena Markowicz-Piasecka, et al.
Published: (2023)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
by: Shubhra Mace, et al.
Published: (2019)

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients
by: Siddhesh A Kamat, et al.
Published: (2015)

Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics
by: David D. Kim, et al.
Published: (2021)

Assessment of oral overlap with antipsychotic long-acting injectables initiated in an inpatient setting
by: Tran Jennifer T. PharmD, et al.
Published: (2023)

Efficacy and safety of long-acting injectable oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis
by: Giovanni Vita, et al.
Published: (2024)

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
by: Francesco Bartoli, et al.
Published: (2023)

Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review
by: Andrea L. Murphy, et al.
Published: (2023)

Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners
by: Shaina Schwartz, PharmD, BCPP, et al.
Published: (2023)

Second-Generation Long-Acting Injectable Antipsychotics and the Risk of Treatment Failure in a Population-Based Cohort
by: Donica Janzen, et al.
Published: (2022)

Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?
by: Carol Paton, et al.
Published: (2022)

An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use
by: Amy M. VandenBerg, PharmD, BCPP
Published: (2022)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
by: Blanca Fernández-Abascal, et al.
Published: (2021)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
by: Mahlich J, et al.
Published: (2015)

Post Hospitalization Clinical Quality Outcomes Among US Patients with Schizophrenia Treated with a Long-Acting Injectable or Switched to a New Oral Antipsychotic: A Retrospective Cohort Study
by: Charmi Patel, et al.
Published: (2023)

Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an modelling study
by: James R. O'Neill, et al.
Published: (2023)

Racial and ethnic differences in patterns of use and discontinuation of long-acting injectable antipsychotics using Medicaid claims data
by: Caballero Joshua PharmD, BCPP, FCCP, et al.
Published: (2023)

Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: Still Daniel PharmD, BCPP, et al.
Published: (2023)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
by: O'Day K, et al.
Published: (2013)

Rural ambulatory care pharmacists providing in-clinic and home visit services improve adherence to long-acting injectable antipsychotics
by: Heng "Helen" Chang, PharmD, BCPS, et al.
Published: (2024)

New atypical antipsychotics for schizophrenia: iloperidone
by: Silvio Caccia, et al.
Published: (2010)

Patients' awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics
by: Jasmina Mallet, et al.
Published: (2024)

Online industry resources can help ensure continuity of care for patients on long-acting injectable antipsychotics while traveling or relocating
by: Brown Geoffrey W PharmD, et al.
Published: (2023)

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
by: Sam Debaveye, et al.
Published: (2019)

Antipsychotics and Mortality in Adult and Geriatric Patients with Schizophrenia
by: Ling-Ling Yeh, et al.
Published: (2023)

Recent trends in antipsychotic polypharmacy in the treatment of schizophrenia
by: Norio Yasui‐Furukori, et al.
Published: (2020)

Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia
by: I. A. Vilyum, et al.
Published: (2018)

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil
by: Marjie L. Hard, et al.
Published: (2019)

Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use"
by: VandenBerg Amy M. PharmD, BCPP
Published: (2023)